Best Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), JetBlue Airways Corporation (NASDAQ:JBLU), First Midwest Bancorp Inc. (NASDAQ:FMBI), Prothena Corporation plc (NASDAQ:PRTA), RCI Hospitality (NASDAQ:RICK)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 297,968 shares at the public offering price of $110.75 per share. The exercise of the over-allotment option brought the total number of shares of common stock sold by Agios to 2,284,423 shares and … Continue reading Best Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), JetBlue Airways Corporation (NASDAQ:JBLU), First Midwest Bancorp Inc. (NASDAQ:FMBI), Prothena Corporation plc (NASDAQ:PRTA), RCI Hospitality (NASDAQ:RICK)

Harvey Dyer12/1712/17

Market Movers: Kosmos Energy Ltd. (NYSE:KOS), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Potlatch Corporation (NASDAQ:PCH), Teleflex Incorporated (NYSE:TFX), BBVA Banco Frances SA (NYSE:BFR)

Kosmos Energy (NYSE:KOS)‘s stock had its “hold” rating reissued by equities research analysts at Citigroup Inc. in a research note issued to investors on Monday. They currently have a $9.50 target price on the stock, down from their previous target price of $12.00. Kosmos Energy Ltd. (NYSE:KOS) belongs to Basic Materials sector. Its net profit margin is 25.30% and weekly performance is -15.90%. On last … Continue reading Market Movers: Kosmos Energy Ltd. (NYSE:KOS), Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), Potlatch Corporation (NASDAQ:PCH), Teleflex Incorporated (NYSE:TFX), BBVA Banco Frances SA (NYSE:BFR)

Harvey Dyer12/1112/11

Ever Green Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), The AES Corporation (NYSE:AES), Wynn Resorts Ltd. (NASDAQ:WYNN), Pioneer Energy Services (NYSE:PES), NovaBay Pharmaceuticals (NYSEMKT:NBY)

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), announced new data from the ongoing Phase 1 dose escalation study of AG-221 as a single agent in patients with IDH2-mutant positive advanced hematologic malignancies. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) belongs to Healthcare sector. Its net profit margin is -82.60% and weekly performance is 11.46%. On last trading day company shares ended up $107.30. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) distance from 50-day simple … Continue reading Ever Green Stocks: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), The AES Corporation (NYSE:AES), Wynn Resorts Ltd. (NASDAQ:WYNN), Pioneer Energy Services (NYSE:PES), NovaBay Pharmaceuticals (NYSEMKT:NBY)

Chris Lewis12/0912/09

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Adam Keintzel07/1007/10

Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of the stock in a transaction dated Monday, June 23rd. The shares were purchased at an average price of $6.84 per share, with a total value of $246,240.00. Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock performance was 3.91% in last session and finished the day at $7.44. Traded volume was 1.38million shares in the last session … Continue reading Biotech Insider Buying: Merrimack Pharmaceuticals (NASDAQ:MACK), Omeros (NASDAQ:OMER), Insys Therapeutics (NASDAQ:INSY), Agios Pharmaceuticals (NASDAQ:AGIO), BioTime (NYSEMKT:BTX)

Ryan Holtz06/2606/26

Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that data from a Phase 1 study of the selective estrogen receptor modulator (SERM) lasofoxifene were featured in a poster presentation today at ICE/ENDO 2014 in Chicago. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) stock performance was -5.92% in last session and finished the day at $62.35. Traded volume was 400.60K shares in the last session and the average volume of the … Continue reading Small Cap Losers: Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), Altisource Asset Management (NYSEMKT:AAMC), Oncomed Pharmaceuticals (NASDAQ:OMED), Agios Pharmaceuticals (NASDAQ:AGIO)

John Meady06/2406/24